tradingkey.logo
tradingkey.logo
Search

WGRX

WGRX
Add to Watchlist
2.980USD
-0.090-2.93%
Close 07/02, 13:00ETQuotes delayed by 15 min
301.90MMarket Cap
LossP/E TTM

TradingKey Stock Score of WGRX

Currency: USD Updated: 2026-07-02

Key Insights

Wellgistics Health Inc's fundamentals are relatively weak, and its growth potential is good.Its valuation is considered fairly valued, ranking 159 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

WGRX's Score

Industry at a Glance

Industry Ranking
159 / 204
Overall Ranking
478 / 4565
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

WGRX Highlights

StrengthsRisks
Wellgistics Health, Inc. is a holding company, which conducts business through two wholly owned subsidiaries, Wood Sage, LLC and Wellgistics LLC and two indirect subsidiaries, Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC. It focuses on specialty medications and a community-based model offering home delivery services to patients. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its technology platform, DelivMeds, serves as a pharmacy hub and allows for clinical services to be connected to the Company’s health pharmacy operations. This platform will allow for an end-to-end mobile application solution whereby patients can digitize their prescription journey. The solution helps to preserve patient autonomy, improve prescription price transparency, and provide additional concierge services. Its products include Kyzatrex and Semaglutide and Tirzepatide.
Growing
The company is in a growing phase, with the latest annual income totaling USD 23.34M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 23.34M.
Undervalued
The company’s latest PE is -3.40, at a low 3-year percentile range.
Held by Steven Cohen
Star Investor Steven Cohen holds 15.25 shares of this stock.

Analyst Rating

Based on 0 analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space